Tags

Type your tag names separated by a space and hit enter

COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 03 28; 395(10229):1033-1034.Lct

Links

Publisher Full Text
ncbi.nlm.nih.gov
linkinghub.elsevier.com
PMC Free PDF
Aggregator Full Text

Authors+Show Affiliations

Mehta P
Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK.
McAuley DF
Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK.
Brown M
Hospital for Tropical Diseases, University College London Hospital, London NW1 2PG, UK.
Sanchez E
Department of Clinical Virology, University College London Hospital, London NW1 2PG, UK.
Tattersall RS
Department of Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK.
Manson JJ
Department of Rheumatology, University College London Hospital, London NW1 2PG, UK. Electronic address: jessica.manson@nhs.net.
HLH Across Speciality Collaboration, UK
No affiliation info available

MeSH

Antirheumatic AgentsBetacoronavirusCoronavirus InfectionsCytokinesHumansImmunization, PassiveImmunoglobulins, IntravenousImmunosuppressionImmunosuppressive AgentsInflammationPandemicsPneumonia, ViralSteroids

Pub Type(s)

Letter

Language

eng

PubMed ID

32192578

Clinical Trial Links

The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
Anti COVID-19 Convalescent Plasma Therapy
Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease
Modulation of Hyperinflammation in COVID-19
Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)
Pilot Study on Cytokine Filtration in COVID-19 ARDS
Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
Using GM-CSF as a Host Directed Therapeutic Against COVID-19
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients
Primary Prevention of Infection by COVID-19 in Health Providers
Evaluation of Immune Response in COVID-19 Patients
Clinical Characteristics and Outcomes of 187 Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection
A Multi-Center Study Evaluating Clinical Course in Patients With COVID19 and Its Relationship to Cytokine Storm
Extracorporeal Blood Purification as a Treatment Modality for COVID-19
Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome
Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients
Clazakizumab vs. Placebo - COVID-19 Infection

Citation

Mehta, Puja, et al. "COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression." Lancet (London, England), vol. 395, no. 10229, 2020, pp. 1033-1034.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England), 395(10229), 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
Mehta P, et al. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. Lancet. 2020 03 28;395(10229):1033-1034. PubMed PMID: 32192578.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19: consider cytokine storm syndromes and immunosuppression. AU - Mehta,Puja, AU - McAuley,Daniel F, AU - Brown,Michael, AU - Sanchez,Emilie, AU - Tattersall,Rachel S, AU - Manson,Jessica J, AU - ,, Y1 - 2020/03/16/ PY - 2020/03/08/received PY - 2020/03/11/accepted PY - 2020/3/21/pubmed PY - 2020/4/4/medline PY - 2020/3/21/entrez SP - 1033 EP - 1034 JF - Lancet (London, England) JO - Lancet VL - 395 IS - 10229 SN - 1474-547X UR - https://www.unboundmedicine.com/medline/citation/32192578/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(20)30628-0 DB - PRIME DP - Unbound Medicine ER -